UK Medtech To Leverage Accelerated Access Opportunity, Regardless Of The 'B' Word

The UK devices and diagnostics industries were quick to react to the long-overdue government response to the fall 2016 Accelerated Access Review, a proposal to fast-track innovation into the NHS to the benefit of UK science, patients and the economy. Coinciding with Brexit, it is a fine-sounding plan, but will there be practical follow-through for medtech too?

Andrew Witty (GSK)
Former GlaxoSmithKline CEO Andrew Witty will be chairing a body to select products for inclusionin the UK Accelerated Access Pathway.

More from United Kingdom

More from Europe